Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
Running, not enrolling · Phase 1 · Has a placebo group
Conditions studied: Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
In brief
The goal of this clinical study is to determine if a single injection of 1 or more dose levels of adeno-associated virus (AAV) gene therapy (GNSC-001) is safe and tolerated compared to placebo in participants with painful osteoarthritis (OA) of the knee.
Key facts
- Study ID
- NCT05835895
- Run by
- Genascence Corporation
- People needed
- 67
- Starts
- 2023-06-12
- Expected to finish
- 2029-05-01
- Last updated by the study team
- 2025-08-01
Who can join
Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Alliance for Medical Research Mobile — Mobile, Alabama, United States
- Biosolutions Clinical Research Center — La Mesa, California, United States
- UC San Diego — San Diego, California, United States
- Well Pharma Medical Research — Miami, Florida, United States
- South Florida Research — Miami Springs, Florida, United States
- Premier Medical Associates — The Villages, Florida, United States
- Alliance for Multispecialty Research Kansas City — Kansas City, Missouri, United States
- West Clinical Research — Morehead City, North Carolina, United States
- Altoona Center for Clinical Research — Duncansville, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.